Table 1 Baseline characteristics
NSCLC | ||
|---|---|---|
Characteristic | Total cohort (N = 20)a | |
Age at diagnosis, years | 68 | (52−82) |
Sex | ||
Male | 11 | (55%) |
Female | 9 | (45%) |
Race | ||
White | 20 | (100%) |
BMI, kg m−2 | ||
BMI < 30 | 15 | (75%) |
BMI ≥ 30 | 5 | (25%) |
ECOG performance status | ||
0 | 10 | (50%) |
1 | 9 | (45%) |
2 | 1 | (5%) |
Stage | ||
IV | 18 | (90%) |
III | 2 | (10%) |
NSCLC histology | ||
Adenocarcinoma | 16 | (80%) |
Squamous cell carcinoma | 4 | (20%) |
Smoking history | ||
Former | 15 | (75%) |
Current | 4 | (20%) |
Never | 1 | (5%) |
PD-L1 | ||
PD-L1 < 90% | 12 | (60%) |
PD-L1 ≥ 90% | 8 | (40%) |
Baseline brain metastases | ||
Absent | 19 | (95%) |
Present | 1 | (5%) |
Prior anti-PD-1 | 6 | (30%) |
Melanoma | ||
Characteristic | Total cohort (N = 20)a | |
Age at diagnosis, years | 56 | (27−88) |
Sex | ||
Male | 13 | (65%) |
Female | 7 | (35%) |
Race | ||
White | 20 | (100%) |
BMI, kg m−2 | ||
BMI < 30 | 11 | (55%) |
BMI ≥ 30 | 9 | (45%) |
ECOG performance status | ||
0 | 17 | (85%) |
1 | 2 | (10%) |
2 | 1 | (5%) |
Stage | ||
IV | 17 | (85%) |
III | 3 | (15%) |
M1 staging | ||
M1a | 8 | (40%) |
M1c | 7 | (35%) |
M1b | 3 | (15%) |
M1d | 2 | (10%) |
BRAF | ||
Wild-type | 10 | (50%) |
Mutant | 9 | (45%) |
Unknown | 1 | (5%) |
BRAF status type | ||
Wild-type | 10 | (50%) |
V600E | 8 | (40%) |
K601E | 1 | (5%) |
Not applicable | 10 | (50%) |
LDH | 8 | (40%) |
LDH normal | 1 | (5%) |
LDH > upper limit of normal | 1 | (5%) |
Baseline brain metastases | ||
Absent | 17 | (85%) |
Present | 3 | (15%) |
Baseline liver metastases | ||
Absent | 18 | (90%) |
Present | 2 | (10%) |
Prior adjuvant anti-PD-1 therapy | ||
No prior anti-PD-1 | 14 | (70%) |
Prior anti-PD-1 | 6 | (30%) |
